Independent Risk Factors of Asthma Exacerbations: 3-year Follow-up in a Single-center Prospective Cohort Study

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2023 Jan 20

PMID 36660650

Authors

Shiyi He

Wanmi Lin

Jingjing Zhong

Xiaoxia Zheng

Yan Jin

Chao Cao

Affiliations

Soon will be listed here.

Abstract

Background: Because minimizing future risk is the goal of asthma chronic asthma management, it is particularly important to identify risk factors. We conducted this 3-year single-center prospective cohort study to determine the independent risk factors of asthma exacerbations (AEs).

Methods: We performed this prospective, longitudinal, observational study with a 3-year follow-up on 257 patients aged 18-81 years with at least a 1-year history of asthma. Follow-up visits are conducted through regular annual phone calls, and the primary endpoints were AE.

Results: The uncontrolled group was more likely to develop AE than the well-controlled group [odds ratio (OR): 6.34, 95% confidence interval (CI): 1.14-35.21, P<0.05]. Patients with low Asthma Quality of Life Questionnaire (AQLQ) scores were more likely to develop AE than these with high AQLQ scores (OR: 0.59, 95% CI: 0.35-0.99, P<0.05). AQLQ and Asthma Control Questionnaires (ACQ) were both strong independent risk factors within 3 years of enrollment; the cut-off values (COV) of the AQLQ and the ACQ (uncontrolled) that better evaluated the risk with the AE were ≤5.4 and >1, respectively. The AQLQ scores had a sensitivity of 79.07% and a specificity of 59.09% [area under curve (AUC): 0.70, P<0.0001], and the ACQ (uncontrolled) had a sensitivity of 81.4% and a specificity of 52.29% (AUC 0.68, P<0.0001).

Conclusions: The findings of this study suggest that patients with uncontrolled asthma and a diminished health-related quality of life had an increased risk of exacerbations in the future. Defining these risk factors associated with AE is important as it will identify these at the highest risk to patients and may guide future interventions.

Citing Articles

Predicting Asthma Exacerbation Risk in the Adult South Korean Population Using Integrated Health Data and Machine Learning Models.

Choi J, Rhee C J Asthma Allergy. 2024; 17:783-789.

PMID: 39157425 PMC: 11330245. DOI: 10.2147/JAA.S471964.

Screening of key genes in childhood asthma based on bioinformatics analysis.

Xia Y, Ling C, Zhan S Transl Pediatr. 2023; 12(5):967-976.

PMID: 37305716 PMC: 10248936. DOI: 10.21037/tp-23-204.

References

Meltzer E, Busse W, Wenzel S, Belozeroff V, Weng H, Feng J . Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol. 2010; 127(1):167-72. DOI: 10.1016/j.jaci.2010.08.042. View

Yue T, Li Q, Wang R, Liu Z, Guo M, Bai F . Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis. Dermatology. 2019; 236(2):170-178. DOI: 10.1159/000498848. View

Vittinghoff E, McCulloch C . Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2006; 165(6):710-8. DOI: 10.1093/aje/kwk052. View

Denlinger L, Phillips B, Ramratnam S, Ross K, Bhakta N, Cardet J . Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med. 2016; 195(3):302-313. PMC: 5328178. DOI: 10.1164/rccm.201602-0419OC. View

Menzies-Gow A, Gurnell M, Heaney L, Corren J, Bel E, Maspero J . Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study. Eur Respir J. 2022; 60(6). PMC: 9791910. DOI: 10.1183/13993003.03226-2021. View

Mitchell A, Meader N, Symonds P . Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis. J Affect Disord. 2010; 126(3):335-48. DOI: 10.1016/j.jad.2010.01.067. View

Bourdin A, Virchow J, Papi A, Lugogo N, Bardin P, Antila M . Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. Respir Med. 2022; 202:106938. DOI: 10.1016/j.rmed.2022.106938. View

Schatz M, Zeiger R, Yang S, Chen W, Crawford W, Sajjan S . The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest. 2011; 141(1):66-72. DOI: 10.1378/chest.11-0574. View

Eisner M, Ackerson L, Chi F, Kalkbrenner A, Buchner D, Mendoza G . Health-related quality of life and future health care utilization for asthma. Ann Allergy Asthma Immunol. 2002; 89(1):46-55. DOI: 10.1016/S1081-1206(10)61910-2. View

10.

Juniper E, Guyatt G, Ferrie P, Griffith L . Measuring quality of life in asthma. Am Rev Respir Dis. 1993; 147(4):832-8. DOI: 10.1164/ajrccm/147.4.832. View

11.

Loymans R, Honkoop P, Termeer E, Snoeck-Stroband J, Assendelft W, Schermer T . Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. Thorax. 2016; 71(9):838-46. DOI: 10.1136/thoraxjnl-2015-208138. View

12.

Hatter L, Houghton C, Bruce P, Holliday M, Eathorne A, Pavord I . Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials. BMJ Open Respir Res. 2022; 9(1). PMC: 9422833. DOI: 10.1136/bmjresp-2022-001271. View

13.

Blanco-Aparicio M, Vazquez I, Pita-Fernandez S, Pertega-Diaz S, Verea-Hernando H . Utility of brief questionnaires of health-related quality of life (Airways Questionnaire 20 and Clinical COPD Questionnaire) to predict exacerbations in patients with asthma and COPD. Health Qual Life Outcomes. 2013; 11:85. PMC: 3701555. DOI: 10.1186/1477-7525-11-85. View

14.

Juniper E, Bousquet J, Abetz L, Bateman E . Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2005; 100(4):616-21. DOI: 10.1016/j.rmed.2005.08.012. View

15.

Wu A, Tantisira K, Li L, Schuemann B, Weiss S, Fuhlbrigge A . Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest. 2011; 140(1):100-107. PMC: 3130529. DOI: 10.1378/chest.10-2794. View

16.

Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R . Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948-68. DOI: 10.1183/09031936.05.00035205. View

17.

Juniper E, OByrne P, Guyatt G, Ferrie P, King D . Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14(4):902-7. DOI: 10.1034/j.1399-3003.1999.14d29.x. View

18.

Osborne M, Pedula K, OHollaren M, Ettinger K, Stibolt T, Buist A . Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest. 2007; 132(4):1151-61. DOI: 10.1378/chest.05-3084. View

19.

Riley R, Ensor J, Snell K, Harrell Jr F, Martin G, Reitsma J . Calculating the sample size required for developing a clinical prediction model. BMJ. 2020; 368:m441. DOI: 10.1136/bmj.m441. View

20.

Menzies-Gow A, Gurnell M, Heaney L, Corren J, Bel E, Maspero J . Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2021; 10(1):47-58. DOI: 10.1016/S2213-2600(21)00352-0. View